Literature DB >> 7911423

Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+ T cell responsiveness.

Y Zevering1, C Khamboonruang, M F Good.   

Abstract

Sequence polymorphism has been reported for virtually all malaria antigens and, in the case of the circumsporozoite (CS) protein, this variation is in the form of point mutations concentrated primarily in several regions recognized by T cells. The factors responsible for the variation are unknown. We studied the T cell responses to all known variants in malaria-exposed Thais. Memory CD4+ T cells responded to variants of a polymorphic immunodominant region (denoted Th2R), and CD4+ T cell clones specific for one Thai Th2R variant were generated. There was minimal cross-reactivity to any of the naturally occurring variants, including the other Thai variant, and competition studies performed with the clones using analog peptides demonstrated that all the substitutions of the polymorphic residues modulate either the binding of the peptide to major histocompatibility complex (MHC) molecules or the recognition by the T cell receptor of the peptide-MHC complex. Our data suggest that CD4+ T cells may be able to select parasites expressing variant sequences and have implications for development of a CS-based vaccine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911423     DOI: 10.1002/eji.1830240627

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

2.  Deletion of Plasmodium berghei-specific CD4+ T cells adoptively transferred into recipient mice after challenge with homologous parasite.

Authors:  C Hirunpetcharat; M F Good
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Plasmodium falciparum antigenic diversity: evidence of clonal population structure.

Authors:  S M Rich; R R Hudson; F J Ayala
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Bottleneck effects on vaccine-candidate antigen diversity of malaria parasites in Thailand.

Authors:  Somchai Jongwutiwes; Chaturong Putaporntip; Austin L Hughes
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

5.  Our impasse in developing a malaria vaccine.

Authors:  Michael F Good
Journal:  Cell Mol Life Sci       Date:  2011-02-15       Impact factor: 9.261

Review 6.  Population structure and recent evolution of Plasmodium falciparum.

Authors:  S M Rich; F J Ayala
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 7.  Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

Authors:  S L Takala; C V Plowe
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

8.  Human and murine T-cell responses to allelic forms of a malaria circumsporozoite protein epitope support a polyvalent vaccine strategy.

Authors:  Y Zevering; C Khamboonruang; M F Good
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

9.  Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2.

Authors:  Simon Franks; Luke Baton; Kevin Tetteh; Eric Tongren; David Dewin; Bartholomew D Akanmori; Kojo A Koram; Lisa Ranford-Cartwright; Eleanor M Riley
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection.

Authors:  Huji Xu; Jiraprapa Wipasa; Huaru Yan; Ming Zeng; Morris O Makobongo; Fred D Finkelman; Anne Kelso; Michael F Good
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.